NOTV

Business Context and Reporting Period

Company: Bioanalytical Systems, Inc. (Note: The filing identifies the registrant as Bioanalytical Systems, Inc., though the request metadata references Inotiv, Inc. The text confirms the company provides contract development services and research equipment for pharmaceutical and biotechnology clients.)

Reporting Period: Fiscal year ended September 30, 2004.

Operations: The company operates in two segments: Contract Research Services (preclinical safety, bioanalysis, clinical trials) and Research Products (robotic blood sampling, analytical instruments). It serves global pharmaceutical companies, with significant operations in Indiana, Maryland, Oregon, and the UK.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 24.5% to $37.2 million. Service revenue grew 24.6% and product revenue grew 24.1%. Growth was driven by the full-year inclusion of two acquired businesses (LC Resources and PharmaKinetics) and increased sales at Baltimore and Evansville locations.
• Profitability Decline: Despite revenue growth, the company reported a net loss of $203,354 compared to a net income of $87,306 in 2003. Operating income dropped from $800,000 to $254,380.
• Margin Compression: Gross margin declined from 34.9% to 31.0%. This was primarily due to lower utilization of capacity in recently acquired facilities, where fixed costs were spread over less-than-capacity revenues.
• Expense Increases: General and administrative expenses rose 37.7% to $7.5 million, partly due to $500,000 in non-recurring consulting fees related to finance department turnover. Interest expense increased to $942,463 due to higher borrowings for acquisitions and construction.
• Client Concentration: Pfizer accounted for approximately 12.5% of total revenues in 2004, down from 16.0% in 2003 (pre-merger consolidation).

Guidance, Outlook, and Risks

• Outlook: Management expects cash from operations and existing credit facilities, combined with proceeds from a recent building sale, to fund working capital and capital expenditures through September 30, 2005. Capital expenditures for fiscal 2005 are estimated at $2.5 million.
• Subsequent Event: On January 5, 2005, the company sold its Baltimore facility for $6.5 million and entered a three-year leaseback. Proceeds were used to pay off the revolving credit facility and increase working capital.
• Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2004, due to decentralized and obsolete accounting systems. A new ERP system is being implemented to address this.
• Accountant Change: The company dismissed Ernst & Young, LLP and appointed KPMG LLP in July 2004. No disagreements were reported, but a material weakness in internal controls regarding loan covenant monitoring was previously identified.
• Risks: Key risks include dependence on a few large clients (e.g., Pfizer), the impact of pharmaceutical industry consolidation, and the ability to achieve full utilization of new capacity to improve margins.

Investor Verification Checklist

• Capacity Utilization: Verify the timeline for filling the new capacity in Baltimore and Evansville to confirm margin recovery projections.
• ERP Implementation: Assess the progress and cost of the new Enterprise Resource Planning system to ensure timely compliance with Sarbanes-Oxley Act Section 404.
• Debt Covenants: Review the specific financial covenants in the credit agreements to ensure the company remains in compliance given the recent net loss.
• Client Diversification: Monitor the revenue mix to ensure reduced reliance on Pfizer following their restructuring and repatriation of preclinical efforts.
• Subsequent Event Impact: Confirm the final terms and cash flow impact of the Baltimore building sale and leaseback transaction completed in January 2005.